IBM Gives Long-Term Sales Growth Outlook That Tops Expectations
International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the expansion in its software business.
Novo Nordisk Expects Slowing Sales Growth This Year
The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs.
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
Novo Nordisk’s Wegovy Drug Sales Miss Expectations
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year.
Novo Nordisk posts net profit beat on Wegovy sales jump, sees growth slowdown this year
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Wegovy sales double but Novo Nordisk sees slower sales growth in 2025
Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly in line with market expectations as the pace of ferocious demand for its wildly popular obesity drug Wegovy eases somewhat.
Novo Nordisk Projects Slower Growth as Wegovy Demand Moderates
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales
Toyota likely to post second straight profit drop as sales growth cools
Japan's Toyota Motor is expected to post its second consecutive quarterly profit drop when it reports third-quarter earnings ...
Yum Brands Projects Stronger Sales Growth This Year
Fast-food restaurant owner Yum Brands is expecting stronger sales growth this year after it moves past challenges in its Middle East markets.
AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China
Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...
Chipotle assesses fallout from Mexico tariffs, forecasts tepid annual sales growth
Chipotle Mexican Grill said on Tuesday that if President Donald Trump's proposed tariffs on Mexico go into full effect, the ...
Zepbound sales keep soaring, even as weight loss drug growth slows
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter, despite missing the company’s initial sales expectations.
Yum! Brands Stock Shines After Q4 Earnings Beat, Fueled By Taco Bell and KFC Growth Engines
Yum! Brands, Inc. (NYSE:YUM) shares are trading higher on Thursday. The company reported fourth-quarter adjusted earnings per ...
Santa Rosa Press Democrat1h
California’s surge in EV sales has stalled — so what happens to its landmark mandate?
About a quarter — 25.3% — of all new cars registered in California in 2024 were electric cars, compared with 25% in 2023. The ...
Gilead: Strong Sales Growth Remains With Veklury And Beyond
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.
Alphabet shares tumble after revenue miss, cloud sales disappoint
Alphabet said on Tuesday it will spend $75 billion on its AI buildout this year, 29% more than Wall Street expected, and ...